HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced Terry Rosen, Ph.D., Chief Executive Officer, and Jennifer
Jarrett, Chief Operating Officer and Chief Financial Officer, will
participate in a fireside chat at the Leerink Partners Roundtable
Series: Rare Disease & Oncology on Wednesday, October 3, 2018, at 10:30
am ET at the Lotte New York Palace, in New York.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist AB928, which is in a Phase 1/1b program to
evaluate AB928 in combination with other agents in multiple tumor types,
and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1
trial and is being tested in combination with Arcus’s other product
candidates. Arcus’s other programs include AB154, an anti-TIGIT
antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy
and in combination with AB122, and AB680, a small molecule inhibitor of
CD73, which is in IND-enabling studies. Arcus has extensive in-house
expertise in medicinal chemistry, immunology, biochemistry, pharmacology
and structural biology. For more information about Arcus Biosciences,
please visit www.arcusbio.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180920005454/en/
Arcus Biosciences
Jennifer Jarrett, 510-694-6261
jjarrett@arcusbio.com
or
Nicole
Arndt, 510-284-4728
narndt@arcusbio.com
Source: Arcus Biosciences